CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7054 result(s)

Milnacipran for Fibromyalgia

Last Updated: February 12, 2008
Result type: Reports

Milnacipran is an antidepressant that is under investigation for the treatment of fibromyalgia (a chronic pain disorder). Preliminary evidence suggests that milnacipran may benefit some patients with fibromyalgia, but adverse effects may limit its use. Complete results of phase 3 trials have not yet been published. Further studies are needed ...

  • Project Number: E0057

Systematic Review and Economic Evaluation of Minimally Invasive Techniques for Total Hip Replacement

Last Updated: February 12, 2008
Result type: Reports

Technology Minimally invasive total hip replacement (MI THR) procedures that involve single- and double- incision techniques. Condition Patients who are eligible for THR due to degenerative, rheumatoid, or other arthritic diseases of the hip. Issue Emerging minimally invasive surgical techniques for hip replacement require specialized equip...

Minimally Invasive Arthroplasty in the Management of Hip Arthritic Disease: Systematic Review and Economic Evaluation

Last Updated: February 12, 2008
Result type: Reports

Technology Minimally invasive total hip replacement (MI THR) procedures that involve single- and double- incision techniques. Condition Patients who are eligible for THR due to degenerative, rheumatoid, or other arthritic diseases of the hip. Issue Emerging minimally invasive surgical techniques for hip replacement require specialized equip...

Continuous Erythropoietin Receptor Activator (Mircera®) for Renal Anemia

Last Updated: February 12, 2008
Result type: Reports

Continuous erythropoietin receptor activator (CERA) is a third-generation erythropoiesis stimulating agent (ESA). CERA is used to correct anemia and maintain hemoglobin levels in patients with renal (kidney) failure. CERA is administered either once every two weeks (to correct anemia) or once per month (to maintain hemoglobin levels). This of...

  • Project Number: E0025